Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Relafen Patent Ruling Clears Way For Trial In 2001

Executive Summary

Patent infringement litigation between SmithKline Beecham and generic companies seeking to launch versions of Relafen (nabumetone) will likely go to trial in the first half of 2001, the company said following an Aug. 16 summary judgment ruling.

You may also be interested in...



Claritin Carcinogenicity Data Central To Protracted Review - GAO

FDA revisited Claritin animal carcinogenicity data and its relevance to humans two and a half years into its review of the Schering-Plough antihistamine following an agency restructuring, the General Accounting Office said in an Aug. 10 report.

SmithKline Beecham Relafen Patent Infringement Trial Set For October

Patent infringement litigation between SmithKline Beecham and three generic companies seeking approval for versions of Relafen (nabumetone) is scheduled to begin in October.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS036563

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel